Biotech News

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

Syndax Pharmaceuticals (SNDX)Syndax Pharmaceuticals2026-06-25 13:46 ESTClinical readout

– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m or KMT2Ar AML shows 97% (34/35) CRc and 86% (25/29)

Open original release

Related news

SNDXSyndax Pharmaceuticals2026-06-25 13:46 EST

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

SNDXSyndax Pharmaceuticals2026-06-25 13:46 EST

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

SNDXSyndax Pharmaceuticals2026-06-25 13:46 EST

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDXSyndax Pharmaceuticals2026-06-25 13:46 EST

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

SNDXSyndax Pharmaceuticals2026-06-25 13:46 EST

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDXSyndax Pharmaceuticals2026-06-25 13:46 EST

Syndax Announces Participation in Upcoming Investor Conferences

SNDXSyndax Pharmaceuticals2026-06-25 13:46 EST

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

SNDXSyndax Pharmaceuticals2026-06-25 13:46 EST

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

SNDXSyndax Pharmaceuticals2026-06-25 13:46 EST

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

SNDXSyndax Pharmaceuticals2026-06-25 13:46 EST

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

View all latest news

Syndax Pharmaceuticals

Syndax Pharmaceuticals is an oncology company focused on targeted therapies and hematologic disease opportunities. Investors watch trial readouts, regulatory milestones, and how the company converts its pipeline into commercial traction.

Recent company news

SNDXSyndax Pharmaceuticals2026-06-26 07:28 EST

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

SNDXSyndax Pharmaceuticals2026-06-26 07:28 EST

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

SNDXSyndax Pharmaceuticals2026-06-26 07:28 EST

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

SNDXSyndax Pharmaceuticals2026-06-26 07:28 EST

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDXSyndax Pharmaceuticals2026-06-26 07:28 EST

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States